Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Подходы к выбору статина для лечения пациентов в амбулаторной практике
Подходы к выбору статина для лечения пациентов в амбулаторной практике
Остроумова О.Д., Дудаев В.А., Щукина Г.Н. Подходы к выбору статина для лечения пациентов в амбулаторной практике. Consilium Medicum. 2015; 1: 44–49. DOI: 10.26442/2075-1753_2015.1.44-49
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье представлен алгоритм обследования больного для решения вопроса о назначении статинов для лечения дислипидемии и атеросклероза. Приведены критерии эффективности терапии статинами. Рассмотрены преимущества аторвастатина и розувастатина. Обсуждается выбор статина для лечения отдельных групп пациентов с учетом изменений в липидном спектре крови.
Ключевые слова: дислипидемия, атеросклероз, аторвастатин, розувастатин, генерики.
Ключевые слова: дислипидемия, атеросклероз, аторвастатин, розувастатин, генерики.
________________________________________________
The paper presents an algorithm of examination of the patient to decide on the appointment of statins for the treatment of dyslipidemia and atherosclerosis. The criteria of the effectiveness of statin therapy. The advantages of atorvastatin and rosuvastatin. We discuss the choice of a statin for the treatment of selected patients with changes in blood lipid spectrum.
Key words: dyslipidemia, atherosclerosis, atorvastatin, rosuvastatin, generics.
Key words: dyslipidemia, atherosclerosis, atorvastatin, rosuvastatin, generics.
Полный текст
Список литературы
1. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр. Атеросклероз и дислипидемии. 2012; 4 (9): 2–52. / Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel'iu profilaktiki i lecheniia ateroskleroza. Rossiiskie rekomendatsii. V peresmotr. Ateroskleroz i dislipidemii. 2012; 4 (9): 2–52. [in Russian]
2. Клиническая фармакология. Под ред. В.Г.Кукеса. М.: ГЭОТАР-Медиа, 2008; с. 648–65. / Klinicheskaia farmakologiia. Pod red. V.G.Kukesa. M.: GEOTAR-Media, 2008; s. 648–65. [in Russian]
3. Sever PS, Dahlof B, Poulter NR et al. For the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.
4. La Rosa J, Grundy SM, Waters DD et al. For the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352 (14): 1425–34.
5. Cannon CP, Braunwald E, McCabe CH et al. For the Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction 22 Investigators. Comparison of Intensive and Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Eng J Med 2004; 350: 1495–504.
6. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96.
7. Amarenco P, Bogousslavsky J, Callahan A 3rd et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59.
8. Мухин В.П., Жиляева Ю.А. Дженерические статины в клинической практике: дешевые заменители или достойная альтернатива брендам. Аторвастатин. Архивъ внутр. медицины. 2012; 2 (4): 72–6. / Mukhin V.P., Zhiliaeva Iu.A. Dzhenericheskie statiny v klinicheskoi praktike: deshevye zameniteli ili dostoinaia al'ternativa brendam. Atorvastatin. Arkhiv" vnutr. meditsiny. 2012; 2 (4): 72–6. [in Russian]
9. Ridker PM, Darielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21): 2195–207.
10. Jones PH, Davidson MH, Stein EA et al and STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152–60.
2. Klinicheskaia farmakologiia. Pod red. V.G.Kukesa. M.: GEOTAR-Media, 2008; s. 648–65. [in Russian]
3. Sever PS, Dahlof B, Poulter NR et al. For the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.
4. La Rosa J, Grundy SM, Waters DD et al. For the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352 (14): 1425–34.
5. Cannon CP, Braunwald E, McCabe CH et al. For the Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction 22 Investigators. Comparison of Intensive and Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Eng J Med 2004; 350: 1495–504.
6. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96.
7. Amarenco P, Bogousslavsky J, Callahan A 3rd et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59.
8. Mukhin V.P., Zhiliaeva Iu.A. Dzhenericheskie statiny v klinicheskoi praktike: deshevye zameniteli ili dostoinaia al'ternativa brendam. Atorvastatin. Arkhiv" vnutr. meditsiny. 2012; 2 (4): 72–6. [in Russian]
9. Ridker PM, Darielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21): 2195–207.
10. Jones PH, Davidson MH, Stein EA et al and STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152–60.
2. Клиническая фармакология. Под ред. В.Г.Кукеса. М.: ГЭОТАР-Медиа, 2008; с. 648–65. / Klinicheskaia farmakologiia. Pod red. V.G.Kukesa. M.: GEOTAR-Media, 2008; s. 648–65. [in Russian]
3. Sever PS, Dahlof B, Poulter NR et al. For the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.
4. La Rosa J, Grundy SM, Waters DD et al. For the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352 (14): 1425–34.
5. Cannon CP, Braunwald E, McCabe CH et al. For the Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction 22 Investigators. Comparison of Intensive and Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Eng J Med 2004; 350: 1495–504.
6. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96.
7. Amarenco P, Bogousslavsky J, Callahan A 3rd et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59.
8. Мухин В.П., Жиляева Ю.А. Дженерические статины в клинической практике: дешевые заменители или достойная альтернатива брендам. Аторвастатин. Архивъ внутр. медицины. 2012; 2 (4): 72–6. / Mukhin V.P., Zhiliaeva Iu.A. Dzhenericheskie statiny v klinicheskoi praktike: deshevye zameniteli ili dostoinaia al'ternativa brendam. Atorvastatin. Arkhiv" vnutr. meditsiny. 2012; 2 (4): 72–6. [in Russian]
9. Ridker PM, Darielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21): 2195–207.
10. Jones PH, Davidson MH, Stein EA et al and STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152–60.
________________________________________________
2. Klinicheskaia farmakologiia. Pod red. V.G.Kukesa. M.: GEOTAR-Media, 2008; s. 648–65. [in Russian]
3. Sever PS, Dahlof B, Poulter NR et al. For the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.
4. La Rosa J, Grundy SM, Waters DD et al. For the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352 (14): 1425–34.
5. Cannon CP, Braunwald E, McCabe CH et al. For the Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction 22 Investigators. Comparison of Intensive and Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Eng J Med 2004; 350: 1495–504.
6. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96.
7. Amarenco P, Bogousslavsky J, Callahan A 3rd et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59.
8. Mukhin V.P., Zhiliaeva Iu.A. Dzhenericheskie statiny v klinicheskoi praktike: deshevye zameniteli ili dostoinaia al'ternativa brendam. Atorvastatin. Arkhiv" vnutr. meditsiny. 2012; 2 (4): 72–6. [in Russian]
9. Ridker PM, Darielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21): 2195–207.
10. Jones PH, Davidson MH, Stein EA et al and STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152–60.
Авторы
О.Д.Остроумова*1,2, В.А.Дудаев1, Г.Н.Щукина1
1 ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*ostroumova.olga@mail.ru
1 ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*ostroumova.olga@mail.ru
________________________________________________
O.D.Ostroumova*1,2, V.A.Dudaev1, G.N.Schukina1
1 A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*ostroumova.olga@mail.ru
1 A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*ostroumova.olga@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.